AdCella Clinical Advisory Board convened
Filed with ASX · · 3 pages · English
AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products, advises that its subsidiary, AdCella Pty Ltd (“AdCella”) has convened a clinical advisory board to advise on clinical development and Phase 1 trial design of BZDS1901, its mesothelin-targeted, armoured CAR-T cell therapy developed to treat mesothelioma and other solid cancers,
Story so far
Earlier from AdAlta
- Half Yearly Report and Accounts
- Quarterly Appendix 4C and Activities Report
- AdCella milestones and regulatory progress
- Placement raises A$1.2 million
- CAR-T collaboration agreement
Later from AdAlta
- AdCella expands clinical advisory board
- New AD-214 patent granted
- AdCella and SHcell hold first JDC meeting
- BZDS1901 clinical update
- Automated cell therapy manufacturing MoU
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta